Last checked at 7 Oct 2022 07:00
Abingdon Health plc
("Abingdon Health" or "the Company")
Judicial Review - judgement expected
York, U.K. 7 October 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, notes that a judgement in relation to the Judicial Review proceedings initiated by the Good Law Project Limited ("GLP") against the Department of Health and Social Care ("DHSC") is expected to be handed down today at 12noon. Abingdon Health is an interested party in the case.
Details are provided in section 17.4 of this link:
https://www.gov.uk/government/publications/business-and-property-courts-rolls-building-cause-list/business-and-property-courts-of-england-and-wales-cause-list#technology-and-construction-court-kings-bench-division
A further announcement will be made once the outcome of the Judicial Review is known.
Enquiries
Abingdon Health plc | www.abingdonhealth.com/investors/ | |
Chris Yates, Chief Executive Officer | Via Walbrook PR | |
Melanie Ross, Chief Financial Officer |
| |
Chris Hand, Non-Executive Chairman |
| |
|
| |
Singer Capital Markets (Sole Broker and Nominated Adviser) | Tel: +44 (0)20 7496 3000 | |
Peter Steel, Alex Bond (Corporate Finance) |
| |
Tom Salvesen (Corporate Broking) |
| |
| ||
Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com | |
Paul McManus / Phillip Marriage Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082 +44 (0)7407 804 654 | |
About Abingdon Health plc
Abingdon Health is a world leading developer and manufacturer of high-quality lateral flow rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York, England.
For more information visit: www.abingdonhealth.com